A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

NCT05775523

Status RECRUITING
Sponsor Ascendis Pharma Endocrinology Division A/S
Enrollment 500 participants

Key Eligibility Criteria

Inclusion (4)

- Paediatric patients with GHD who are on treatment with lonapegsomatropin
- Patients being clinically managed in Europe or the USA
- Appropriate written informed consent/assent as applicable for the age of the patient
- Patients willing to comply with follow-up requirements of the study

Exclusion (7)

- Patients participating in any interventional clinical trial for short stature
- Patients being treated with a GH or IGF-1 therapy, other than lonapegsomatropin, at enrollment
- Patients for whom treatment with lonapegsomatropin is contraindicated
- Patients with closed epiphyses
- Patients with active malignant tumours

... and 2 more (see full listing online)

Locations (27 total)

Ascendis Investigational Site, Phoenix, Arizona, United States
Ascendis Investigational Site, Orange, California, United States
Ascendis Investigational Site, Sacramento, California, United States
... and 24 more locations